Skip to content | Change text size
 

Dr David M Shackleford

Image of Dr David M Shackleford

Biopharmaceutics section leader, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

BAppSc (Hons) University of South Australia
PhD University of South Australia

Telephone: +61 3 9903 9065
Fax: +61 3 9903 9052
Email: david.shackleford@pharm.monash.edu.au

Section leader, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

Research interests

  • The development, establishment and application of lead optimisation technologies to rapidly identify, design and select the best drug discovery candidates for further pre-clinical and clinical development

Representative publications

  1. Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, et.al. Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism. Pharmaceutical Research.  In Press 2009.
  2. Gujjar R, Marwaha A, El Mazouni F, White J, White K, Shackleford D, et. al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with anti-malarial activity in mice. Journal of Medicinal Chemistry. In Press 2009.
  3. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Lymphatic absorption of orally administered prodrugs. D.M. Shackleford, C.J.H. Porter and W.N. Charman. In Prodrugs: Challenges and Rewards, Part 1, Eds. Washington DC: Springer AAPS Press. 2007; 653-682.
  4. Shackleford DM, Evans AM, Milne RW, Nation RL. Loading-Washout Studies of the Stereoselective Sinusoidal Uptake of (R)- and (S)-2-Phenylpropionyl Acyl Glucuronide. Current Drug Metabolism. 2006; 7(7):817-826.
  5. Wang J, Nation RL, Evans AM, Cox S, Shackleford D. Metabolism and Disposition of the antiviral nucleoside AM365 in the isolated perfused rat liver. Current Drug Metabolism. 2005; 6(5):487-493.
  6. Shackleford DM, Nation RL, Milne RW, Hayball PJ, Evans AM. Stereoselective Hepatic Disposition of Model Diastereomeric Acyl Glucuronides . Journal of Pharmacokinetics and Pharmacodynamics. 2004; 31(1):1-27.
  7. Lucas AN, Brogan LR, Nation RL, Milne RW, Shackleford DM, et. al. The Effects of the Phytoestogenic Isoflavone Genistein on the Hepatic Disposition of Preformed and Hepatically-Generated Gemfibrozil 1-O-Acyl Glucuronide in the Isolated Perfused Rat Liver. Journal of Pharmacy and Pharmacology. 2003; 55(10):1433-1439.
  8. Khoo SM, Shackleford DM, Porter CJH, Edwards, GA, Charman WN. Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs. Pharmaceutical Research. 2003; 20(9):1460-1465.
  9. Shackleford DM, Faassen WA, Houwing N, Lass H, Edwards GA, Charman WN. Contribution of Lymphatically Transported Testosterone to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs. Journal of Pharmacology and Experimental Therapeutics. 2003; 306(3):925-933.
  10. Shackleford DM, Porter CJH, Charman WN. Does Stereoselective Lymphatic Absorption Contribute to the Enantioselective Pharmacokinetics of Halofantrine In Vivo? Biopharmaceutics and Drug Disposition. 2003; 24(4):153-157.
  11. Shackleford DM, Prankerd RJ, Charman WN. Self-Micellisation of Gemfibrozil 1-O-β Acyl Glucuronide in Aqueous Solution. Pharmaceutical Research. 2003; 20(3):465-470.
  12. Shackleford DM, Hayball PJ, Reynolds GD, Hamon DPG, Evans AM, Milne RW, et.al. A small-scale synthesis and enantiomeric resolution of (RS)-[1-14 C]-2-phenylpropionic acid and biosynthesis of its diastereomeric acyl glucuronides. Journal of Labelled Compounds and Radiopharmaceuticals. 2001; 44(3):225-234.